Amedisys (AMED)
(Delayed Data from NSDQ)
$98.01 USD
+0.09 (0.09%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $98.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.01 USD
+0.09 (0.09%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $98.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
New Strong Sell Stocks for December 2nd
by Zacks Equity Research
AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.
New Strong Sell Stocks for November 26th
by Zacks Equity Research
COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.
New Strong Sell Stocks for November 19th
by Zacks Equity Research
AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
BLMN, AMED, HL, LGIH, and PLMR have been added to the Zacks Rank #5 (Strong Sell) List on November 5, 2021.
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.
Amedisys (AMED) Beats Q3 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.50% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LHC Group (LHCG) Finalizes Home Health & Hospice Buyout Deals
by Zacks Equity Research
LHC Group (LHCG) to expand in Virginia Beach with the completion of the previously announced acquisition agreements with two providers, one in home health and the other in hospice.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Amedisys (AMED) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health's (EHC) Growth View Makes It a Good Buy
by Sapna Bagaria
Ageing population, building of hospitals and other operational efforts poise Encompass Health (EHC) well for long-term growth, thus making it a good investment option.
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Amedisys (AMED) Beats Q2 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 3.05% and -0.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.
Amedisys (AMED) Latest New York Assets Buyout Aids Home Health
by Zacks Equity Research
The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.